Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.66 |
| ▸ | NPC1 | O15118 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | P4HTM | Q9NXG6 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.53 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.50 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12020850 | 0.92 | RAB9A (0.57) | RAB9ANPC1MEN1KMT2ARXFP1 | |
| SCHEMBL12020864 | 0.91 | MEN1 (0.70) | RAB9ANPC1MEN1KMT2ARXFP1 | |
| SCHEMBL12020925 | 0.91 | P4HTM (0.57) | RAB9ANPC1MEN1KMT2ARXFP1 | |
| SCHEMBL12020359 | 0.91 | P4HTM (0.57) | RAB9ANPC1MEN1KMT2ARXFP1 | |
| SCHEMBL12020444 | 0.88 | P4HTM (0.62) | RAB9ANPC1MEN1KMT2ARXFP1 | |
| SCHEMBL12020360 | 0.88 | NPC1 (0.56) | RAB9ANPC1MEN1KMT2ARXFP1 | |
| SCHEMBL12020732 | 0.87 | MEN1 (0.55) | RAB9ANPC1MEN1KMT2ARXFP1 | |
| SCHEMBL9566760 | 0.86 | RAB9A (0.60) | RAB9ANPC1MEN1KMT2ARXFP1 | |
| SCHEMBL12020926 | 0.85 | MAPT (0.56) | MEN1KMT2ARXFP1KDM4ELMNA | |
| SCHEMBL12020427 | 0.84 | NPC1 (0.58) | RAB9ANPC1MEN1KMT2ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969389-B2 | Substituted 6-methylnicotinamides as mGluR5 positive allosteric modulators | VANDERBILT UNIVERSITY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20110294858-A1 | SUBSTITUTED 6-METHYLNICOTINAMIDES AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294858-A1 | SUBSTITUTED 6-METHYLNICOTINAMIDES AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | GRM5, GRIK5, GRM6 | RAB9A 2376/4885NPC1 2704/4885MEN1 3758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.